66
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls

, , , , , & show all
Pages 2139-2147 | Published online: 06 Sep 2016

Figures & data

Table 1 Subject demographics

Figure 1 nSMase-2 labeling in human lung tissue.

Notes: Representative images for nSMase-2 expression (brown) within the peripheral lung tissue from (A, D, G) NS, (B, E, H) S, and (C, F, I) COPD patients. nSMase-2 was detected within the small airway epithelium (AF) with a more pronounced expression toward the apical surface (inset arrow). nSMase-2 was also detected within the alveolar macrophages and alveolar walls (GI). nSMase-2-positive alveolar macrophages (black arrows) observed near alveolar macrophages lacking nSMase-2 expression (red arrows). Magnification ×200 (AC) ×600 (DI).

Abbreviations: NS, nonsmoker; S, smoker.

Figure 1 nSMase-2 labeling in human lung tissue.Notes: Representative images for nSMase-2 expression (brown) within the peripheral lung tissue from (A, D, G) NS, (B, E, H) S, and (C, F, I) COPD patients. nSMase-2 was detected within the small airway epithelium (A–F) with a more pronounced expression toward the apical surface (inset arrow). nSMase-2 was also detected within the alveolar macrophages and alveolar walls (G–I). nSMase-2-positive alveolar macrophages (black arrows) observed near alveolar macrophages lacking nSMase-2 expression (red arrows). Magnification ×200 (A–C) ×600 (D–I).Abbreviations: NS, nonsmoker; S, smoker.

Figure 2 Quantification of nSMase-2 in lung tissue.

Notes: All data are presented in graphs as means and standard errors of the mean. (A) The percentages of intact small airways with nSMase-2 labeling, (B) the number of cells with nSMase-2 labeling per mm2 of the subepithelium, (C) the number of cells with nSMase-2 labeling per mm of the alveolar wall, and (D) the percentage of alveolar macrophages with nSMase-2 labeling. *P<0.05 according to Dunnett’s multiple comparison test.
Figure 2 Quantification of nSMase-2 in lung tissue.

Figure 3 aSMase labeling in human lung tissue.

Notes: Representative images for aSMase expression (brown) within the peripheral lung tissue from (A, D, G) NS, (B, E, H) S, and (C, F, I) COPD patients. aSMase was detected within the small airway epithelium (AF) with a pronounced nuclear expression (inset arrow). aSMase was also detected within the alveolar macrophages and alveolar walls (GI). aSMase-positive alveolar macrophages (black arrows) observed near alveolar macrophages lacking nSMase-2 expression (red arrows). Magnification ×200 (AC) ×600 (DI).

Abbreviations: NS, nonsmoker; S, smoker.

Figure 3 aSMase labeling in human lung tissue.Notes: Representative images for aSMase expression (brown) within the peripheral lung tissue from (A, D, G) NS, (B, E, H) S, and (C, F, I) COPD patients. aSMase was detected within the small airway epithelium (A–F) with a pronounced nuclear expression (inset arrow). aSMase was also detected within the alveolar macrophages and alveolar walls (G–I). aSMase-positive alveolar macrophages (black arrows) observed near alveolar macrophages lacking nSMase-2 expression (red arrows). Magnification ×200 (A–C) ×600 (D–I).Abbreviations: NS, nonsmoker; S, smoker.

Figure 4 Quantification of aSMase labeling in lung.

Notes: All data are presented in graphs as means and standard errors of the mean. (A) The percentages of intact small airways with aSMase labeling, (B) the number of cells with aSMase labeling per mm2 of the subepithelium, (C) the number of cells with aSMase labeling per mm of the alveolar wall, and (D) the percentage of alveolar macrophages with aSMase labelling. *P<0.05 according to Dunnett’s multiple comparison test.
Figure 4 Quantification of aSMase labeling in lung.

Figure 5 nSMase-2 and aSMase gene expression in alveolar macrophages.

Notes: RNA was extracted from NS (n=4), S (n=13), and COPD (n=14) alveolar macrophages. Complementary DNA was synthesized by RT-PCR and analyzed for (A) nSMase-2 and (B) aSMase expression using Taqman gene expression primers in a QPCR. Relative expression levels were determined using the ΔCt method normalizing to the endogenous control (GAPDH). Both box and whisker plots illustrate data as medians with the maximum/minimum values out with the upper/lower quartile.
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, reverse transcription polymerase chain reaction; QPCR, quantitative polymerase chain reaction; NS, nonsmoker; S, smoker.
Figure 5 nSMase-2 and aSMase gene expression in alveolar macrophages.

Figure 6 Quantification of ceramide species (C16, C18, and C20) in alveolar macrophages.

Notes: Ceramide species (C20, C16, and C18) were quantified by mass spectrometry. A significant increase in C20 but not in C16 or C18 was observed in alveolar macrophages from COPD patients (n=10) compared with non-COPD patients (n=7), according to Dunnett’s multiple comparison test.
Figure 6 Quantification of ceramide species (C16, C18, and C20) in alveolar macrophages.